EBV-specific TCR-T cells with cytokine auto-secreting element

drug_type

RELEVANT_DRUG

intervention_type

Cellular therapy (TCR-T; autologous gene-engineered T cells)

drug_description

Autologous, gene-engineered adoptive T-cell therapy in which patient T cells are transduced with an EBV-epitope-specific TCR and engineered to secrete a cytokine upon activation, enabling HLA-restricted recognition and killing of EBV-positive tumor cells and enhancing antitumor immunity.

nci_thesaurus_definition

NCI thesaurus definition not available.

drug_mesh_term

Adoptive Immunotherapy

drug_category

ENGINEERED TCR T

drug_class

Cellular Therapy

drug_delivery_route

Intravenous

drug_mechanism_of_action

Autologous T cells engineered to express an EBV epitope–specific TCR recognize EBV peptides presented by HLA on tumor cells, triggering TCR signaling and cytotoxic killing. Upon activation, the cells auto-secrete a cytokine that enhances their function, persistence, and recruitment/activation of endogenous immune cells, boosting antitumor immunity in EBV-positive tumors.

drug_name

EBV-specific TCR-T cells with cytokine auto-secreting element

nct_id_drug_ref

NCT04509726